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Introduction: Exhaled carbon monoxide (eCO) has been widely implicated as a pulmonary biomarker in respiratory
diseases. The aim of this study was to investigate whether the treatment of patients with severe acute exacerbation of
chronic obstructive pulmonary disease (AECOPD) could be aided by monitoring the changes in eCO.Methods: The
levels of eCO along with routine clinical parameters were analyzed in 29 current smoker and 33 ex-smoker COPD
patients, ﬁrst at the time of hospital admission, and again at discharge following the standard treatment. Patients with
AECOPD were also stratiﬁed according to sputum bacteria. Results: At exacerbation, the levels of eCO were
increased in current smokers compared to ex-smokers (6.0 [2.0–9.5] versus 1.0 [1.0–2.0] ppm, p< 0.001). Similarly,
eCO levels were higher in smokers after treatment (7.0 [2.0–12.5] versus 1.0 [1.0–2.0] ppm, p< 0.001). Treatment of
AECOPD did not affect eCO concentrations. The levels of eCO were not statistically different between bacterial and
non-bacterial AECOPD either. Investigating a subgroup of current smoker patients (n= 15), there was a signiﬁcant
correlation between the levels of eCO and blood carboxyhemoglobin concentrations both at exacerbation and
discharge. No associations were found between eCO and lung function or blood gas parameters. Conclusion: Our
results suggest that monitoring eCO during the treatment of AECOPD is of limited clinical value.
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Introduction
Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are associated
with an increased inﬂammation and oxidative stress (16). Exhaled breath analysis has
enormous potential as an easy non-invasive mean of monitoring these processes in the
airways (11).
One of the simple gases present in the exhaled breath that has been suggested to reﬂect
ongoing oxidative stress and/or airway inﬂammation is carbon monoxide (CO) (9, 25). The
measurement of exhaled CO (eCO) is a brief non-invasive procedure that provides immediate
results, and is most commonly measured with electrochemical technology.
Increased concentration of eCO has been demonstrated in several inﬂammatory lung
diseases including asthma (12), bronchiectasis (13), and cystic ﬁbrosis (CF) (21). Several
recent studies have reported the elevated levels of eCO in COPD as well (18, 20). However,
eCO levels may also be elevated in healthy smokers due to the high CO content of cigarette
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smoke (6, 7). Nevertheless, eCO concentrations are also increased in ex-smokers with COPD
that may be the result of enhanced oxidative stress in the lungs (18).
In addition to these ﬁndings, the potential application of eCO for monitoring the
effectiveness of anti-inﬂammatory therapeutics in patients with airway viral (5, 29) and/or
bacterial (19) infections has also been suggested. In some animal models, systemic bacterial
infection was also associated with an increased CO concentration in exhaled breath (3).
Only a few studies have investigated the changes in eCO levels in patients with
AECOPD, and it is unclear whether common treatment with corticosteroids and broncho-
dilators modiﬁes eCO during recovery. Moreover, it is unknown whether eCO measurement
may assist in the selection of patients who would probably have a bacterial AECOPD. It is
well established that bacterial infections play a pivotal role in the pathogenesis of AECOPD
(4), and predicting bacteriological origin of an exacerbation might be of high clinical
importance.
Therefore, this longitudinal study was undertaken to determine whether eCO concen-
trations are modiﬁed along with recovery as a result of treatment in patients with severe
AECOPD. In addition, the levels of eCO were analyzed in relation with the results of
conventional sputum bacterial culture.
Materials and Methods
Study subjects
Patients hospitalized with AECOPD were recruited for the study. Inclusion and exclusion
criteria are summarized in Fig. 1. Exacerbation was deﬁned as increased dyspnea, cough, or
sputum expectoration (quality or quantity) that led the subject to seek medical attention, as
Fig. 1. Flowchart showing the study proﬁle. COPD: chronic obstructive pulmonary disease
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speciﬁed in international guidelines (23). The research protocol was approved by the local
ethics committee, and all the subjects gave written informed consent to participate in the study.
Study design
The levels of eCO, blood gases, and lung function parameters were measured at two time
points: ﬁrst at hospital admission of the patients, and again on the day of discharge following
the treatment. White blood cell (WBC) count and C-reactive protein (CRP) values were
measured in venous blood samples at hospital admission. In addition, in the subgroups of
smoker (n= 15) and ex-smoker (n= 19) patients, the levels of carboxyhemoglobin (HbCO)
in arterialized capillary blood taken from the ears were determined using a blood gas analyzer
both at exacerbation and after treatment. Measurements at exacerbations were performed
before treatment in all patients. Lung function and blood gas parameters were determined, as
previously described (2).
Sputum bacterial culture
At hospital admission, sputum was collected upon spontaneous expectoration in sterile vials
from all patients. Samples were processed locally for Gram stain and routine bacteriological
culture. Identiﬁcation was performed on all potentially pathogenic microorganisms (PPMs)
including Streptococcus pneumoniae, Haemophilus inﬂuenzae, Moraxella catarrhalis, and
Pseudomonas aeruginosa according to standardized protocols (10). Since the signiﬁcance of
other bacteria such as Staphylococcus aureus and Haemophilus parainﬂuenzae is debated
(20), these agents were not considered as PPMs. Similarly, other bacterial species in sputum
were classiﬁed as normal ﬂora, in line with other studies (27).
Measurement of eCO
The levels of eCO were measured using a portable CO monitor (Smokerlyzer Micro, Bedfont
Scientiﬁc Ltd., Kent, UK). The results were given in parts per million (ppm). According to the
manufacturer’s speciﬁcations, the sensitivity of the sensor is 1 ppm, while the accuracy of the
device is ±2 ppm.
Statistical analysis
Data are presented as mean ± SEM or median with interquartile range as appropriate. Data
distribution was analyzed by the Kolmogorov–Smirnov test. eCO and HbCO levels between
the current smoker and ex-smoker patients or bacterial and non-bacterial AECOPD were
analyzed by the Mann–Whitney test. Paired Student’s t-test (parametric data) and the
Wilcoxon signed-rank test (non-parametric data) were used to compare the measurements
at the time of hospital admission and the measurements at discharge. Correlation coefﬁcients
were calculated by Spearman’s method. Power calculation was performed with α= 0.05 and
0.78 effect size. The calculations were performed by GraphPad Prism 4.0 (GraphPad
Software Inc., San Diego, CA, USA) and G*Power 3.1.1 (G*Power Software Inc., Kiel,
Germany) software packages. A p-value <0.05 was considered signiﬁcant.
Results
About 79 patients with AECOPD were screened; 69 fulﬁlled inclusion criteria (Fig. 1).
During hospital treatment, seven patients were excluded. Demographic and clinical data of
the 29 smoker and 33 ex-smoker patients who completed the study are presented in Table I.
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Treatment of AECOPD
Patients with AECOPD showed the disturbance of lung function, hypoxia, and increased
systemic inﬂammatory markers (WBC: 14.2 ± 2.4 × 109/L and CRP: 44.1 ± 8.8 mg/L).
Exacerbations were treated with systemic (i.v. or oral) glucocorticoids and bronchodilators
Table I. Demographic and clinical characteristics of study subjects
Smoker COPD Ex-smoker COPD
Subjects (n) 29 33
Sex (male/female, n) 15/14 18/15
Age (years) 62.3 ± 1.8 68.3 ± 1.9
Smoking (pack-years) 40.2 ± 4.4 38.0 ± 3.6
GOLD stages (n, %)
I 5 (17) 7 (22)
II 14 (48) 12 (36)
III 8 (28) 12 (36)
IV 2 (7) 2 (6)
Pulmonary medicationc (n, %)
ICS 22 (76) 21 (64)
LABA 24 (83) 24 (73)





FVC (L) 2.1 ± 0.1 2.3 ± 0.1** 2.0 ± 0.1 2.2 ± 0.2*
FVC (% predicted) 69.6 ± 3.8 78.0 ± 4.4** 72.2 ± 3.6 83.7 ± 5.1*
FEV1 (L) 1.0 ± 0.1 1.2 ± 0.1** 0.9 ± 0.1 1.2 ± 0.1***
FEV1 (% predicted) 42.9 ± 3.1 48.8 ± 3.5** 43.8 ± 4.4 55.4 ± 3.6***
FEV1/FVC (%) 50.3 ± 2.9 50.4 ± 3.0 48.3 ± 3.5 55.4 ± 3.6***
PaO2 (kPa) 7.5 ± 0.4 7.6 ± 0.3 7.1 ± 0.2 7.9 ± 0.2**
PaCO2 (kPa) 5.4 ± 0.3 5.5 ± 0.2 5.5 ± 1.2 6.1 ± 0.3
HbCO (%)ab 3.0 (2.2–3.3) 2.9 (2.5–3.4) 2.7 (1.6–2.8)**** 2.3 (1.7–2.9)****
Data are presented as mean ± SEM unless stated otherwise. GOLD: global initiative for chronic obstructive lung
disease, FVC: forced vital capacity, FEV1: forced expiratory volume in 1 s, PaCO2: arterial carbon dioxide tension,
PaO2: arterial oxygen tension, HbCO: carboxyhemoglobin, ICS: inhaled corticosteroid, LABA: long-acting
β2-agonist, and LAMA: long-acting muscarinic antagonist.aMedian (interquartile ranges), bobtained from 15 smoker
and 19 ex-smoker patients, cbefore hospital admission. *p< 0.05, **p< 0.01 or ***p< 0.001 after treatment versus
admission, ****p< 0.05 ex-smoker versus smoker patients.
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(anticholinergics and/or β2-agonists) in all cases. Antibiotics were given to 44 patients. The
mean length of hospitalization was 12.5 ± 2.9 days. As expected, lung function variables and
PaO2 improved signiﬁcantly along with clinical recovery of the patients by the time of
discharge (Table I).
Sputum culture with PPMs was found in 17 patients (H. inﬂuenzae: eight patients,
S. pneumoniae: ﬁve patients, M. catarrhalis: two patients, and P. aeruginosa: two patients).
In 33 cases, sputum culture was negative or indicated bacteria of the normal respiratory ﬂora
only. In the remaining 12 patients, the obtained sputum was not considered as a representative
bronchial sample.
eCO measurements
At exacerbation, the levels of eCO were signiﬁcantly increased in smokers compared to ex-
smokers (6.0 [2.0–9.5] versus 1.0 [1.0–2.0] ppm, p< 0.001). Similarly, eCO concentrations
were higher in smokers after treatment (7.0 [2.0–12.5] versus 1.0 [1.0–2.0] ppm, p< 0.001)
(Fig. 2). No signiﬁcant differences were detected between eCO levels at exacerbation and
after treatment (p> 0.05), irrespective of patients’ smoking status. The power of the study
was 97.6% to detect a standardized difference in eCO between the smoker patients at
exacerbation and after treatment. Patients receiving inhaled corticosteroids (ICS) had slightly
reduced the eCO levels compared with those not taking ICS at admission, but the difference
was not signiﬁcant (data not shown).
To further explore the potential clinical utility of eCO measurements, patients with
AECOPD were stratiﬁed by bacterial culture results at exacerbation. However, eCO levels
were similar between the bacterial and non-bacterial exacerbations irrespective of whether the
subjects were smokers or ex-smokers (smokers: 9.0 [4.0–11.5] versus 6.0 [2.0–9.5] ppm,
p> 0.05; ex-smokers: 2.0 [2.0–3.0] versus 1.0 [0.5–2.0] ppm, p> 0.05).
HbCO measurements
In agreement with the ﬁndings in eCO, the levels of HbCO in the blood were also elevated in
smoker patients compared to ex-smoker subjects, both at exacerbation and discharge
(Table I). HbCO levels at exacerbation and after treatment were similar.
Fig. 2. Levels of exhaled carbon monoxide
(eCO) in smoker (n= 29) and ex-smoker
(n= 33) COPD patients at the time of an acute
exacerbation (ex) and after hospital treatment
(treat). Horizontal bars represent the median
values. ppm: parts per million. *p< 0.001
ex-smokers versus smokers
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Correlations
In the subgroup of current smoker patients (n= 15), a signiﬁcant correlation was observed
between eCO and HbCO concentrations, both at exacerbation (r= 0.561, p< 0.05) and
discharge (r= 0.574, p< 0.05) (Fig. 3). In the subgroup of ex-smoker subjects (n= 19), eCO
and HbCO levels did not correlate (data not shown). No signiﬁcant correlations were
observed between the eCO values and clinical variables, lung function, or blood gas
parameters (data not shown).
Discussion
The aim of this study was to assess whether common treatment with corticosteroids and
bronchodilators modiﬁes eCO concentrations in patients hospitalized with AECOPD. We
have observed no change in eCO during hospitalization indicating that the treatment of or
recovery from an exacerbation is not mirrored in eCO levels in patients with COPD. This is
reminiscent to some earlier ﬁndings where no difference in eCO was found in stable COPD
patients with and without corticosteroid treatments (20). Similarly, in subjects with asthma,
there was no difference in eCO between patients who were taking ICS and those who were
not (22). Moreover, the expression of different heme-oxygenase isoenzymes responsible, at
least in part, for the biosynthesis of CO in the airways may also be independent of ICS
therapy in asthmatic patients (17). Importantly, our study was sufﬁciently powered to detect a
clinically meaningful change in eCO between the patients before and after treatment. Thus,
contrary to early expectations and some promising ﬁndings in CF (1) and asthma (30), eCO
does not appear to be a useful biomarker to monitor inﬂammation and/or oxidative stress in
patients with AECOPD.
We have also demonstrated that eCO concentrations are higher in current smoker
patients compared to ex-smoker subjects, both at onset and after treatment of AECOPD. This
ﬁnding agrees with the previous studies showing that smoker COPD patients have elevated
eCO values compared to ex-smokers (18). Smoking one cigarette results in an approximately
three-fold increase in eCO concentrations, and active smokers may have up to 20–25 ppm CO
in their exhaled breath (14). In our study, smokers had slightly lower eCO levels than these
values, which could be explained by reduced smoking frequency of the patients prior
hospitalization due to their poor clinical status and severe dyspnea.
Fig. 3. Correlation between exhaled carbon monoxide (eCO) and blood carboxyhemoglobin (HbCO) concentrations
at the time of an acute exacerbation (a) and after hospital treatment (b) assessed in a subset of current smoker
patients (n= 15)
216 Antus et al.
Physiology International (Acta Physiologica Hungarica) 103, 2016
Endogenously produced CO diffuses to the blood where it is transported by hemoglobin
in the form of HbCO and is released to the alveolar space during gas exchange (9, 25).
Therefore, the measurement of blood HbCO concentration may also be a marker to monitor
the severity of local and/or systemic oxidative stress in a wide variety of pulmonary and
extrapulmonary diseases. In line with this view, Yasuda et al. have recently demonstrated that
blood HbCO concentrations in arteries and peripheral veins are increased in patients with
asthma, COPD, and pneumonia compared to healthy subjects (31). Moreover, they observed
a close correlation between eCO and HbCO levels in these conditions. Interestingly, in
patients with COPD, HbCO correlated with eCO only at moderate stages of COPD severity
(GOLD stages II and III) but not at advanced stage (GOLD stage IV) (32).
In our study, we have shown that HbCO levels are increased in smokers compared to ex-
smokers, both at exacerbation and after treatment. Moreover, HbCO and eCO levels showed
a signiﬁcant correlation in smokers. Interestingly, Wald et al. found a tighter correlation
between eCO and HbCO values compared to our data (0.97 versus 0.56) (28). However, this
study (28) was performed on a large cohort of healthy smokers and eCO was assessed by a
different technique. In line with our ﬁndings about eCO, treatment of AECOPD did not
modify blood HbCO concentrations either. Thus, like on eCO levels, smoking but not
disease activity (exacerbation versus convalescence) has a major impact on blood HbCO
concentrations.
Although the etiology of AECOPD is heterogeneous, bacterial infections may play a
signiﬁcant role in the development of AECOPD (4). Since eCO has been widely implicated as
a biomarker of respiratory infections (5, 19, 29), we investigated whether eCO concentrations
differ between bacterial and non-bacterial AECOPD. This is an important issue, since on
clinical grounds it is difﬁcult to predict a bacterial course of AECOPD which requires
antibiotic treatment. Nonetheless, eCO levels were comparable between bacterial and non-
bacterial exacerbations indicating that eCO cannot serve as a biomarker to identify those
cases where a bacterial agent is likely to contribute to AECOPD. We are aware that AECOPD
may be triggered by viral infections as well; however, for the lack of available data, this
analysis could not be carried out.
It has been shown that both eCO and HbCO levels change toward the normal values in
smokers within 12–24 h after temporary cessation of smoking (15, 26). In our study,
however, these marker levels remained elevated by the time of hospital discharge. Since ex-
smokers exhibited almost normal eCO concentrations, it is not likely that persistent airway
inﬂammation could account for this ﬁnding. We speculate that although smoking is
prohibited in our hospital, some patients continued to smoke during treatment, which could
have an effect on our results. Indeed, as also indicated in the literature, the compliance of
smokers with hospital no-smoking policies is often poor (24).
It should be noted that eCO levels in ex-smoker COPD patients were in the range of
theoretical sensitivity of the detection method. In contrast, eCO values in smokers were
markedly higher compared to these values. Thus, although marker levels in ex-smoker
subjects should be interpreted with caution, smokers can be reliably discriminated from ex-
smokers using this device. Consequently, this eCO measurement methodology is widely
accepted by experts on this ﬁeld of research (12, 13, 21, 26, 29–32).
Of importance, we found no correlation between the eCO levels and lung function
parameters in our study. Similarly, in a population survey of smokers from the
Copenhagen Heart Study, eCO values were found to have no correlation with lung
function or lung function decline in smokers either (8). Other authors have also failed to
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observe any association between eCO and lung function indices in stable patients with
COPD (18).
In conclusion, although the measurement of eCO is feasible in patients with AECOPD
requiring hospitalization, the clinical applicability of the test to monitor airway inﬂammation
and/or oxidative stress during recovery from an exacerbation is limited. Similarly, eCO
measurement does not appear to be useful to identify the cases of AECOPD with bacterial
etiology either.
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